BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/30/2024 6:47:30 AM | Browse: 55 | Download: 382
 |
Received |
|
2024-09-14 02:35 |
|
Peer-Review Started |
|
2024-09-14 02:35 |
|
First Decision by Editorial Office Director |
|
2024-10-15 21:32 |
|
Return for Revision |
|
2024-10-15 21:32 |
|
Revised |
|
2024-10-28 09:17 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-11-20 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-11-20 06:42 |
|
Articles in Press |
|
2024-11-20 06:42 |
|
Edit the Manuscript by Language Editor |
|
2024-11-27 00:42 |
|
Typeset the Manuscript |
|
2024-12-05 02:49 |
|
Publish the Manuscript Online |
|
2024-12-30 06:47 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Adrián Cortés-Martín and Julio Plaza-Diaz |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Julio Plaza-Diaz, PhD, School of Health Sciences, Universidad Internacional de La Rioja, Avenida de la Paz 137, Logrono 26006, La Rioja, Spain. julioramon.plaza@unir.net |
| Key Words |
Glucagon-like peptide 1 agonists; Liver diseases; Metabolic dysfunction-associated steatotic liver disease; Metabolic health; Pharmacotherapy; Diet; Gut microbiome; Physical exercise; Lifestyle; Non-alcoholic fatty liver disease |
| Core Tip |
This article comments on Soresi and Giannitrapani’s work concerning glucagon-like peptide 1 agonists as potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease. The integration of dietary changes and regular physical exercise into treatment may improve patient outcomes. These lifestyle adjustments may reduce the reliance on pharmacological interventions and/or increase the effectiveness of existing treatments. Therefore, lifestyle factors should not be overlooked in the broader strategy for managing metabolic dysfunction-associated steatotic liver disease, since they complement medical therapies. |
| Publish Date |
2024-12-30 06:47 |
| Citation |
Cortés-Martín A, Plaza-Diaz J. Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders. World J Gastroenterol 2025; 31(4): 101436 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i4/101436.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i4.101436 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
